International Journal of Progressive Sciences and Technologies (IJPSAT) ISSN: 2509-0119. © 2022 Scholar AI LLC. Vol. 34 No. 2 September 2022, pp. 437-449 Corresponding Author: Maged Naser 437 Biomarkers In Prediction Of Preeclampsia Maged Naser 1 , Mohamed M. Naser 2 , Lamia H. Shehata 3 1 Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Ob/Gyn, 2 King Fahd Hospital, Ministry of Health, Kingdom of Saudi, Department of Surgery, Consultant Endoscopic Surgery, 3 Department of Radiology Care National Hospital, KSA Abstract – Preeclampsia is being pregnant-specific, and notably contributes to maternal, and perinatal morbidity and mortality worldwide. An effective predictive test for preeclampsia could facilitate early diagnosis, focused surveillance and well timed delivery; however, restrained alternatives presently exist. A first-trimester screening algorithms has been evolved and demonstrated to expect preterm preeclampsia, with poor utility for term disease, wherein the greatest burden lies. Biomarkers consisting of sFlt-1 and placental growth factor also are now getting used clinically in cases of suspected preterm preeclampsia; their high negative predictive value allows assured exclusion of disease in women with normal results, however sensitivity is modest. There has been a concerted attempt to become aware of ability novel biomarkers that could enhance prediction. These in large part originate from organs concerned in preeclampsia’s pathogenesis, which includes placental, cardiovascular and urinary biomarkers. This review outlines the clinical imperative for an effective test and those already in use and summarises modern-day preeclampsia biomarker studies. Keywords – preeclampsia, Placental transcriptomics, placental genes, Liquid biopsy, proteomics. I. INTRODUCTION 1. Preeclampsia syndrome Preeclampsia includes dire effects for the mother and fetus, subsequently one of the major goals of prenatal follow-up is the early detection of the development of this syndrome. Its onset is multifactorial, it could arise at diverse gestational ages, and it could show different grades of severity [1–6]. The modern-day classification is primarily based totally at the onset and the severity of signs; however, it does now no longer as it should reflect the underlying pathophysiological processes. Based on this classification, we distinguish early-onset (<34 weeks) and late-onset (≥34 weeks), or preterm (<37 weeks) and term (≥37 weeks), preeclampsia [2]. Early-onset or preterm preeclampsia is more often complicated by fetal growth restriction (FGR) and more severe symptoms as compared to late-onset or term preeclampsia [1,2,4,5]. In preterm preeclampsia, the extravillous trophoblast dysfunction and the ensuing impairment of spiral artery remodelling are of paramount significance in its pathogenesis. Decreased uteroplacental perfusion and ischemic stress cause an imbalance in angiogenic and antiangiogenic factors, ensuing in endothelial damage, systemic infection, and multiorgan failure [3,7–20]. In term period preeclampsia, the impact of diverse chronic stressors consisting of obesity, diabetes, and kidney, metabolic or autoimmune disease is more dominant [21–30] and maternal vascular and endothelial reaction can also be more sensitive to placental factors [31,32]. Genetic elements related to angiogenesis and immune interactions among the mother and the fetus also are key for the susceptibility to preeclampsia [33–41]. Due to those pathophysiological variations, early-onset or preterm preeclampsia may be greater as it should be expected within the first trimester via way of means of an aggregate of maternal characteristics and biophysical and biochemical markers as compared to late-onset preeclampsia [42]. Improved prediction can probable be expected if the heterogeneous pathophysiological pathways and their specific biomarkers are recognized. Although considerable progress has been made with the expertise of preeclampsia the use of clinical epidemiology, astute observations by clinicians, and